<DOC>
	<DOCNO>NCT02657408</DOCNO>
	<brief_summary>The primary secondary objective current study assessment anti-inflammatory pharmacodynamic effect segmental endotoxin induce inflammatory response 4 week treatment BI 1026706 .</brief_summary>
	<brief_title>Clinical Trial Assess Pharmacodynamic Effects Segmental Endotoxin Induced Inflammatory Response BI 1026706 Versus Placebo</brief_title>
	<detailed_description />
	<criteria>Inclusion criterion : Signed informed consent consistent ICHGCP guideline local legislation prior participation trial . Healthy volunteer sex 18 65 year ( inclusive ) age , day subject 's signature inform consent . Healthy subject assess investigator , base screen examination include medical history , physical examination , vital sign ( blood pressure , pulse rate , body temperature ) , 12lead ECG , lung function clinical laboratory result . FEV1 ( Forced expiratory volume ) &gt; 80 % FEV1/FVC ( Forced vital capacity ) &gt; 70 % predict normal value screen Current smoker smoke history least 1 pack year least 1 cigarette per day previous year BMI ( Body mass index ) range : &gt; 18.5 &lt; 29.9kg/m2 . Negative urine drug screening . Negative breath alcohol test . Negative skin prick test ( perform within 12 month prior study start study start ) Females NOT childbearing potential define : Women postmenopausal ( 12 month menses without alternative medical cause ; questionable case blood sample simultaneous level FSH 40 U/L estradiol 30 ng/L confirmatory ) permanently sterilize ( defined hysterectomy , bilateral oophorectomy bilateral salpingectomy ) . Further inclusion criterion apply Exclusion criterion : History relevant lung disease ( i.e . COPD , asthma , chronic bronchitis , pulmonary fibrosis , pulmonary alveolar proteinosis ( PAP ) , pneumocystis infection , active tuberculosis , silicosis lung surfactant overproduction syndrome ) . Subjects clinically relevant abnormal hematology , blood chemistry , urinalysis screen visit Any finding medical examination ( include blood pressure , pulse rate , body temperature ECG ) deviate normal clinical relevance . Subjects history clinically significant cardiovascular , metabolic , renal ( include renal stone ) , hepatic , gastrointestinal , hematological , dermatological , venereal , neurological , psychiatric major disorder . Subjects malignancy subject undergone resection , radiation therapy chemotherapy within last five year . Subjects treat basal cell carcinoma fully cure squamous cell carcinoma allow participate . Subjects previous surgery gastrointestinal tract likely affect drug absorption . History relevant orthostatic hypotension , faint spell blackout . Subjects clinically relevant infection know ongoing clinically relevant inflammatory process . History relevant allergy/hypersensitivity include allergy drug excipients medication line bronchoscopy ( bronchodilator , sedatives local anesthetic ) . Subjects mark baseline prolongation QT/QTcB interval ( repeat demonstration QTcB interval &gt; 450 m ) , relevant ECG find screen visit ( Visit 1 ) accord investigator . Neutrophil blood count indicative immunosuppression accord investigator screen visit ( Visit 1 ) . Subjects previous surgery may leave ferromagnetic material body , ferromagnetic implant pacemaker . Participation another study investigational product within 2 month prior screen screen occurs within 6 halflives intake another investigational drug ( whichever great ) . Male subject agree minimize risk female partner become pregnant first dose day 3 month trial medication treatment finish . Subjects committed institution way official juridical order enrol trial . Receipt live ( attenuate ) vaccine within 4 week prior screen trial . Subject assess unsuitable inclusion investigator ; instance , consider able understand comply study requirement condition would allow safe participation study . For female subject : Positive pregnancy test screen Visit 1 , pregnancy plan become pregnant within 30 day study completion Lactation Further exclusion criterion apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>